| Stereochemistry | RACEMIC |
| Molecular Formula | C25H31NO.ClH |
| Molecular Weight | 397.981 |
| Optical Activity | ( + / - ) |
| Defined Stereocenters | 3 / 3 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
Cl.[H][C@]12C[C@](O)(CCN1C[C@]3([H])C4=C(CCC5=C3C2=CC=C5)C=CC=C4)C(C)(C)C
InChI
InChIKey=QZRUMKUMFJJARD-OMMJFLKZSA-N
InChI=1S/C25H31NO.ClH/c1-24(2,3)25(27)13-14-26-16-21-19-9-5-4-7-17(19)11-12-18-8-6-10-20(23(18)21)22(26)15-25;/h4-10,21-22,27H,11-16H2,1-3H3;1H/t21-,22-,25-;/m1./s1
Butaclamol is an antipsychotic drug, which was studied for the treatment of schizophrenia. This drug has never marketed and now is used in research, because of its action as a dopamine receptor-blocking agent. Butaclamol consists of the two forms: (-)-butaclamol, an inactive drug and (+)-butaclamol, a potent neuroleptic drug.
CNS Activity
Approval Year
PubMed
Patents
Sample Use Guides
Maximum clinical response appeared to be at the 20-40 mg. dose level. Extrapyramidal signs occurred at all doses, but with greater severity at higher doses. Excessive daytime drowsiness occurred in all groups but with longer duration and greater intensity in the 20 mg. group.
Route of Administration:
Intraperitoneal
ACTIVE MOIETY
SUBSTANCE RECORD
